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Available online 3 June 2016Background: Glucocorticoid therapy is used widely in patients with rheumatoid arthritis (RA) with good efﬁcacy
but concerns about safety including fractures. Estimates of fracture risk for any given patient are complicated by
the dynamic pattern of glucocorticoid use, where patients vary in their dose, duration and timing of glucocorti-
coid use.
Objective: To investigate which methods are currently used to attribute fractures to glucocorticoid exposure and
investigate whether such methods can consider individual treatment patterns.
Results: Thirty-eight studies used ﬁve common deﬁnitions of risk attribution to glucocorticoid exposure: “current
use”, “ever use”, “daily dose”, “cumulative dose” and “time variant”. One study attempted to combine multiple
deﬁnitions where “cumulative dose” was nested within “daily dose”, covering the effects of dose and duration
but not timing. Themajority of results demonstrated an equivocal or increased risk of fracturewith increased ex-
posure, although there was wide variation, with odds ratios, hazard ratios and relative risks ranging from 0.16 to
8.16.Within deﬁnitions there was also variability in the results with the smallest range for “time variant”, 1.07 to
2.8, and the largest for “cumulative dose”, ranging from risk estimates of 0.88 to 8.12.
Conclusion:Many studies have looked into the effect of glucocorticoids on fracture risk in patients with RA. De-
spite this, there is no clear consensus about the magnitude of risk. This is a consequence of the varied analysis
models and their different assumptions. Moreover, no current analysis method allows consideration of dose, du-
ration and timing of glucocorticoid therapy, preventing a clear understanding of fracture risk for patients and
their individual treatment patterns.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Rheumatoid arthritis (RA) is an autoimmune disease which affects
between 0.5 and 1% of the population [1]. Glucocorticoids were identi-
ﬁed as a treatment for RA over 60 years ago [2] and approximately 2/3
of patients have ever used glucocorticoids [3]. They have been found
to reduce joint tenderness and pain [4], and to reduce the rate of disease
progression when used in addition to standard therapies [5]. Whilst re-
ducingdisease progression, there are adverse effects associatedwith the
use of glucocorticoids, including bone fracture, infection, cataracts, and
diabetes [6]. Glucocorticoid use tends to be dynamic, with patients
switching between periods of use and non-use, and with varying
doses through time in response to their disease severity. Thus most pa-
tients have a personalised treatment plan.
Glucocorticoids primarily affect bone health and fracture risk by act-
ing on functions critical in the regeneration and healing cycles [7]. Glu-
cocorticoids have been shown to affect the function of both osteoclasts
and osteoblasts, resulting in disruption to bone repair. This impact on
bone remodelling weakens the bone making it more brittle and at
higher risk of fracture [8]. The brittleness of the bones also causes a re-
duction in bone mineral density (BMD) for those on glucocorticoids
and hence an increase in the risk of fracture has been found at levels
of BMD where the patient does not have osteoporosis [9] suggesting
they affect fracture risk above and beyond the usual effect of decreasing
BMD. Despite the acceptance that glucocorticoid therapy increases the
risk of fracture, estimates about the size of the effect vary widely. This
may be because a wide range of deﬁnitions has been used to attribute
fractures to glucocorticoid exposure.
It is likely that the impact of glucocorticoids on fracture risk relates
to the dose administered, the duration of exposure, the latency between
administration and effect on bone regeneration, and post-exposure re-
covery [10]. This review will therefore investigate the range of different
deﬁnitions used to attribute fractures to glucocorticoid exposure in pa-
tients with RA, and investigate the impact of these different deﬁnitions
on the results. The assumptions of each deﬁnition of glucocorticoid ex-
posure will be assessed for suitability with regards to the dynamic pat-
terns of glucocorticoid exposure experience by patients with RA by
reviewing their consideration of dose, duration and timing.
2. Methods
A literature search was carried out in Ovid using the databases
Medline and Embase. For both databases the years covered by the
search were from the conception of the database until the end of Octo-
ber 2014.
The search criteria used for inclusion of papers included terms for
glucocorticoids, fractures, and RA, (see Appendix) and were the same
for both databases. Searches were initially limited to English language,
humans, adults with further limitations made to the publication type.
In Medline, publication types removed included: case reports, Phase I
or II clinical trials, reviews, meta analyses, duplicate publications,
retracted publications and any other non-research article publications.
In Embase, publication types removed included books, book series, con-
ference papers, editorials, notes, reviews and short surveys. Following
exclusions, abstracts were screened to ensure the topic of the paperwas suitable and if no abstract was available within Ovid, attempts
were made to ﬁnd the paper online.
3. Results
Fig. 1 describes the number of papers found at each stage of the lit-
erature search with the reasons papers were discarded.
During a qualitative synthesis stage, a further 16 papers were ex-
cluded either because there was no analysis of effect of glucocorticoids
on fracture reported (5 papers), only 1 fracture occurring in either the
glucocorticoid exposed or unexposed cohorts (2 papers), no association
between glucocorticoids and fracture was reported (5 papers), RA was
not considered in the paper (2 papers) or if the English full text version
was not available (2 papers).
Thirty eight papers were selected for review (Table 1). The deﬁni-
tions for attributing fractures to glucocorticoid exposure were as fol-
lows: “current use” (n = 19), “ever use” (n = 15), “daily dose” (n =
13), “cumulative dose” (n= 8), “multi-variable” (n=2), “time variant”
(n = 8) and other deﬁnitions of glucocorticoid exposure (n= 3). Mul-
tiple deﬁnitionswere reported in 17 papers. Thesemodels are described
further in Fig. 2 using a hypothetical dynamic exposure pattern for an
individual patient.
3.1. Descriptions with binary response
Two deﬁnitions of glucocorticoid exposure were binary variables.
Firstly the “current use” deﬁnition, which meant the participant was
on glucocorticoids at the time of fracture and secondly the “ever use”
deﬁnition, which attributed an incident fracture to glucocorticoid use
if a participant had ever taken glucocorticoids during the study period.
In the exposure pattern for a hypothetical patient shown in Fig. 2, “cur-
rent use” at the time of fracture would be 0 (i.e. the patient is off drug at
the time of fracture and the fracture is thus not attributed to their gluco-
corticoid exposure) and “ever exposed”would be 1 (i.e. they HAVE ever
been exposed to glucocorticoid therapy and the fracture would be at-
tributed to their historical exposure.)
Of the 19 papers that reported results for “current use” of glucocor-
ticoids, nine [15–20,25,26,28,29] found a statistically signiﬁcant in-
crease in the risk of fracture, ﬁve [11,14,21–23] found no signiﬁcant
change in the risk of fracture, one [24] found a decreased risk of fracture,
one found an increased risk in women but not men and the remaining
three [12,13,27] found an increased risk at some fracture sites but not
others. Those who found an increased risk of fracture had an odds
ratio, relative risk or hazard ratio between 1.33 [13] and 4.15 [15] for
current users compared to non-users whereas the paper that reported
a decreased risk had an odds ratio of 0.17 for current users compared
to the general population [24].
Within the 15 papers reporting “ever use” of glucocorticoids, six [20,
21,30,33,37,41] found an increased risk of fracture, ﬁve [31,32,36,38,40]
found no statistically signiﬁcant change in the risk of fracture, two [34,
39] found an increased risk at some fracture sites but not others, one
[19] found an increased risk for certain age groups and one [35] report-
ed an increased risk in women but not men. Within the six papers that
reported an increased risk, only two reported odds ratios, relative risk or
hazard ratios with values of 1.69 [35] and 8.16 [41].
Fig. 1. Flow diagram.
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use” and “ever use” methods of attributing fractures to glucocorticoid
exposure, limited to vertebral fractures. A single fracture type was se-
lected to reduce other causes of heterogeneity, enabling a comparison
of the impact of analysismethodology on the results. Vertebral fractures
were chosen since the majority of papers (29/39 studies (74%)) report-
ed on either clinical or radiographic vertebral fractures.
Fig. 3 demonstrates that the increased risk of vertebral fracture was
not consistent within the “current use” deﬁnition, with one “current
use” paper having a relative risk around 2, with one “current use”
paper having a relative risk around 3, and three “current use” papers
having an odds ratio about 4. Fig. 3 demonstrates that the increased
risk of vertebral fracture was not consistent within the “current use”
deﬁnition, with one “current use” paper having a relative risk around
2, with one “current use” paper having a relative risk around 3 Three
“current use” papers had an odds ratio about 4 whilst one had an odds
ratio of around 0.2. A meta-analysis of these odds ratios for “current
use” would generate approximately a fourfold increased risk of verte-
bral fracture. Furthermore, Fig. 3 illustrates through their absence that
12/15 publications considering “ever use” reported P-values only and
no point estimate, and are hence missing.3.2. Descriptions of dose
Two methods were used to attribute fractures to deﬁnitions of
glucocorticoid exposure which demonstrated the effect of dose.
Firstly the “daily dose” deﬁnition which described the dose the par-
ticipant was on at the time of fracture and secondly the “cumulative
dose” deﬁnition which described the total dose taken during the pa-
tients follow-up. In the hypothetical exposure pattern described in
Fig. 2, the “daily dose” would be 0 mg and the “cumulative dose”
2.85 g. These two dose-speciﬁc deﬁnitions were also combined in
two papers describing the effect of dose and duration in a multi-var-
iable model.
Of the 13 papers using “daily dose” of glucocorticoid, nine [21,23,25–
27,37,38,41,42] papers found an increased risk of fracture with increas-
ing dose, one [40] found no statistically signiﬁcant change in risk, one
[22] found an increased risk for women but not men and two [24,39]
did not report statistics regarding “daily dose” although theymentioned
recording “daily dose”. The odds ratios for thosewho found an increased
risk ranged from 1.03 [22] to 2.03 [41] when “daily dose” was consid-
ered as a continuous variable (per mg per day) and 1.60 [26] (for
b7.5 mg/day compared to past use) to 4.5 [38] (for 5–10 mg/day
Table 1
Results of literature search.
Ref. Design Population type Comparator population Study methodology n Fracture type OR/RR/HR/P-value
CU EU DD CD ML TV OT
Van
Everdingen
[11]
Double blinded
randomised
control trial
RA patients given
prednisone
RA patients given placebo ✓ 40 +
41
Vertebral fracture Not signif, OR not
given
Furuya [12] Prospective
cohort
RA patients using
GC
RA patients not using GC ✓ 1733 Vertebral, main non
vertebral and any
non-vertebral
RR: Vt
1.90 (0.61, 5.94),
any Non-Vt
1.69 (1.01,2.83)
Coulson [13] Retrospective
cohort
RA patients, GC use RA patients, non GC use ✓ 8419 Any, vertebral, hip
and non-vertebral,
non-hip fracture
RR: any fracture 1.325
signif, Vt 1.211 not
signif no CI given
Hooyman
[14]
Retrospective
cohort
Females with RA
with fracture of
interest
Female with RA without
fracture of interest
✓ 388 Femur, humerus,
pelvis, forearm,
vertebral
RR: femur fracture
2.15 (0.79, 4.67)
Orstavik [15] Retrospective
cohort
Early RA patients
long term GC use
Early RA patients none or
short term GC use
✓ 249 Vertebral fracture OR: 4.15 (1.70,10.07)
Verstraeten
[16]
Retrospective
cohort
Postmenopausal
women with RA
Postmenopausal controls ✓ 147 Vertebral fracture P value b0.01
Cooper [17] Case control RA patients
admitted to
orthopaedic unit
Community controls 1:2
matched
✓ 300 +
600
Hip fracture OR: 2.5 (1.1, 5.5)
Butler [18] Case control
from cohort
Rheumatology
patients taking low
dose GC therapy
Rheumatology patients
not taking GC therapy
✓ 142 Any fracture P-value b0.05
Araia [19] Cross sectional RA patients Healthy patients admitted
for osteoporosis
evaluation
✓ 117 Vertebral fracture OR: 3.82 (3.01, 4.85)
Orstavik [20] Retrospective
cohort
Established RA
patients
General population ✓ ✓ ✓ 528 Vertebral fracture P-values CU & EU
b0.001
RR: TV 1.55 (1.03,
2.33)
Kay [21] Case control RA patients with
fracture
RA patients no fracture ✓ ✓ ✓ ✓ 18 +
18
Stress fracture P-values: CU 0.32, EU
0.02, DD 0.0003, TV
0.06
Furuya [22] Prospective
cohort
RA patients using
GC
RA patients not using GC ✓ ✓ 9720 Hip fracture HR: CU not signif.
DD: men no change,
women 1.03 (1.00,
1.06)
Furuya [23] Prospective
cohort
RA patients using
GC
RA patients not using GC ✓ ✓ 1020 Non-vertebral and
vertebral fracture
HR: CU not signif.
DD: Vt 1.28 (1.14,
1.45)
Non-Vt 1.01 (0.86,
1.18)
Ghazi [24] Case control RA patients General population ✓ ✓ 101 +
303
Vertebral fracture OR: CU 0.17 (0.04,
0.66)
DD not reported
de Nijs [25] Cross sectional RA patients using
oral GC on daily
basis ≥1 month
RA patients not using GC
matched 1:1
✓ ✓ ✓ 410 Vertebral fracture OR: CD 1.00 no CI
CU 4.31 (1.13, 16.47)⁎
DD: 1.16 (1.05, 1.28)⁎
De Vries [26] Retrospective
cohort
RA patients with
current GC use
RA patients with past GC
use
✓ ✓ ✓ ✓ 191,752 Osteoporotic, hip
and vertebral
fracture
RR: Osteo
CU 1.68 (1.6, 1.76)
DD b7.5 mg 1.60 (1.50,
1.71)
7.5–15 mg 2.15 (1.97,
2.34)
CD b1gb 1.38 (0.59,
3.22)
1–5gb 8.12 (5.19,
12.74)
Nampei [27] Prospective
cohort
RA patients taking
GC
Different strength or
duration of GC use
✓ ✓ ✓ 209 Any, vertebral and
“lower leg and
pelvis” fracture
OR: all
DD 1.174 (1.054,
1.306)
TV 1.095 (1.015,
1.181)
pelvis
DD 1.195 (1.043,
1.370)
TV 1.131 (1.033,
1.239)
Maghraoui
[28]
Cross sectional RA patients using
GC
RA patients, non-current
use and different category
of cumulative use
✓ ✓ 172 Vertebral fracture P-value CD b0.0001
Mazzantini
[29]
Retrospective
cohort
GC users ≥6 months Never use of GC ✓ ✓ 2359 Osteoporotic
fracture
P-value CU b0.02
TV N5 years b0.001
b2 and 2–5 years
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Table 1 (continued)
Ref. Design Population type Comparator population Study methodology n Fracture type OR/RR/HR/P-value
CU EU DD CD ML TV OT
N0.05
Michel [30] Retrospective
cohort
RA patients with GC
use
RA patients not using GC ✓ 395 Any fracture RR: 1.9, P-value 0.026
Wright [31] Prospective
cohort
Arthritis patients
using GC
Patients not using GC ✓ 147,657 Any, hip and clinical
spine fracture
P-value N0.05
Araia [19] Prospective
cohort
RA patients using
GC
RA patients not using GC ✓ 112 Vertebral fracture P-value b0.05 for age
groups 50–54 and
60–64
Saville [32] Cross sectional RA patients taking
GC
RA patients not taking GC ✓ 164 Vertebral fractures P-value N0.05
Laan [33] Cross sectional RA patients taking
GC
RA patients not taking GC ✓ 77 Vertebral fractures P-value 0.03
Vis [34] Prospective
cohort
Established RA
patients using GC
RA patients not on GC ✓ 102 Vertebral and
non-vertebral
fracture
P-value: V 0.04,
Non-V 0.30
Lapi [35] Retrospective
cohort
Those taking GC Those not taking GC ✓ 271,121 Osteoporotic and hip
fracture
OR: Osteo: male 1.39
(0.98, 1.97) female
1.69 (1.42, 2.01)
Peel [36] Case control Postmenopausal
women with RA
Population based ✓ 76 +
347
Vertebral fracture Non signif
Ochi [37] Prospective
cohort
RA patients with
fracture
RA patients no fracture ✓ ✓ 9987 Distal radius HR: DD 1.07 (1.01,
1.13)
EU: higher % GC users
in fracture group
Saag [38] Case control Early RA, N1 year CS
use
Early RA, 1:1 matched, no
GC use
✓ ✓ 112 +
112
Any fracture P-value EU N0.05
5–10 mg/d 4.5 (2.1,
9.6)
Lems [39] Case control RA patients treated
with GC on daily
basis ≥1 month
Rheumatology patients
not using GC
✓ ✓ 52 +
55
Vertebral or
peripheral fracture
P-values: Vt 0.03,
peripheral N0.05
Baskan [40] Cross sectional RA patients Healthy patients ✓ ✓ ✓ 156 Vertebral fracture P-value N0.05
Sugiyama
[41]
Prospective
cohort
Rheumatic disease
patients on high
dose GC
Rheumatic disease
patients not on GC
✓ ✓ ✓ ✓ 2631 Vertebral fracture HR: EU 8.16 (1.09,
60.86)
DD 2.03 (1.43, 2.88)
CD 0.88 (0.84, 0.93)
OT various
Sugiyama
[42]
Prospective
cohort
Early RA patients
high dose GC
Early RA patients not on
GC
✓ ✓ ✓ 700 Vertebral fracture
(symptomatic)
HR: DD 1.24 (1.16,
1.33)
CD 0.92 (0.91, 0.94)
OT various
Sinigaglia
[43]
Retrospective
cohort
Established RA
patients GC use
Established RA patients no
GC use
✓ 925 Vertebral fracture OR: CD 1.03 (1.006,
1.07)
Lespessailles
[44]
Cross sectional RA patients using
GC
Non GC users ✓ ✓ 146 Vertebral and any
fracture
OR: any: CD 0–5 vs
15+
4.04 (1.5, 11.2)
TV 0–12 vs 60+
months
2.8 (1.07, 7.3)
Angeli [45] Cross sectional RA patients with
high cumulative
dose
RA patients with low
cumulative dose
✓ ✓ 551 Vertebral fracture P-values all N0.05
Van Staa [46] Retrospective
cohort
Oral GC patients No GC prescription in past
3 months
✓ 191,752 Osteoporotic, hip
and vertebral
fracture
RR: Vt: various results:
e.g.
DD b2.5, CD b1
2.11 (0.87, 5.10)
DD b2.5, CD N1
3.22 (2.09, 4.95)
Michel [47] Case control RA patients with
fracture
RA patients without
fracture
✓ 226 +
884
Any fracture OR: 1.07 (1.04, 1.11)
Van Staa [9] Retrospective
cohort
RA patients Population based 1:3
matched
✓ 121,045 Osteoporotic, hip
and vertebral
fracture
RR: N. prescriptions
0 prescript 1.5 (1.2,
1.9)
1–2 prescript 2.9 (1.9,
4.4)
N2 prescript 5.5 (4.4,
6.8)
Abbreviations: CU= current use, EU= ever use, DD= daily dose, CD= cumulative dose, ML=multi-level, TV = time variant, OT= other, OR= odds ratio, RR = relative risks, HR=
hazard ratio, RA = rheumatoid arthritis, GC = glucocorticoid(s), Vt = vertebral fracture, Non-Vt = non-vertebral fracture, Osteo = osteoporotic fracture, signif = signiﬁcant, N. =
number.
a The two results by Arai [19]were produced in the same paper in a studywhich originally started as a cross sectional study but extended inmost patients to a Prospective Cohort study.
⁎ Crude odds ratios.
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Fig. 2. A hypothetical patient's exposure to glucocorticoids. Footnote: at 20 months:
current use = No, ever use = Yes, daily dose = 0 mg, cumulative dose = 2.85 g, time
variant = 12 months on glucocorticoids.
Fig. 4. The odds ratios (circles), and hazard ratios (diamonds) with 95% conﬁdence
intervals showing the information given from the daily dose and cumulative dose
methods of deﬁning glucocorticoid exposure using results deﬁning vertebral fractures.
112 D.E. Robinson et al. / Bone 90 (2016) 107–115compared to never treated patients) when “daily dose”was considered
categorically.
Of the eight papers reporting “cumulative dose”, four [26,28,43,44]
reported an increased risk of fracture with increasing cumulative expo-
sure, two [25,45] reported no change to the risk of fracture and two [41,
42] reported a decreased risk of fracture. The odds ratios for those who
found an increased risk ranged from 1.03 [43] to 4.31 [26] per gram in-
crease as a continuous variable whilst those who found a decreased risk
ranged from 0.88 [41] to 0.92 [42] per gram increase. When considered
as a categorical variable the results ranged from 1.38 [29] if b1 g had
been consumed compared to past glucocorticoid use to 8.12 [29]
when between 1 and 5 g had been consumed compared to past gluco-
corticoid use.
A plot of the differences within estimates of fracture risk from “daily
dose” and “cumulative dose” are demonstrated in Fig. 4.
Two [26,46] papers nested “cumulative dose”within “daily dose” to
provide a multi-variable model. This method showed a statistically sig-
niﬁcant increase risk of fracture for most combinations of “daily dose”
and “cumulative dose” suggesting that there is a combination of effect
from both “daily dose” and “cumulative dose”.Fig. 3. The odds ratios (circles), relative risks (triangles) and hazard ratios (diamonds)
with 95% conﬁdence intervals showing the information given from the two binary
methods, current use and ever use using results deﬁning vertebral fractures.3.3. Descriptions of duration
One commonly used deﬁnition described duration of glucocorticoid
therapy, the “timevariant”deﬁnitionwhichdescribed the change in risk
of fracture by the length of time spent on glucocorticoids. In the hypo-
thetical exposure pattern described in Fig. 2, the duration spent on glu-
cocorticoids was 12 month. Eight papers reported a time variant model
of which four [20,27,44,47] reported an increased risk of fracture with
increasing exposure, three [21,40,45] reported no signiﬁcant change
and one [29] found an increased risk for those who had taken glucocor-
ticoids for greater than 5 years compared to non- users. The odds ratios
for those who found an increased risk ranged signiﬁcantly from 1.07/
year [47] to 2.8/month [44].3.4. Other methods for attributing fractures to glucocorticoid exposure
Of the three papers who reported other methods of deﬁning gluco-
corticoid exposure, one [9] investigated the effect of the number of pre-
scriptions in the past six months and two [41,42] investigated multiple
methods of glucocorticoid exposure including pulse therapy, initial
daily dose and number of dose increases.
Nometa-analysiswas attempted due to heterogeneity in the studies,
such as the different fracture types, different comparator populations,
study designs, different confounders, and small study numbers once
stratiﬁed by risk attribution model.4. Discussion
Five common methods were identiﬁed within this literature review
that deﬁned risk attribution of fracture risk to oral glucocorticoids in pa-
tientswith RA: “current use”, “ever use”, “daily dose”, “cumulative dose”
and “time-variant”. A multi-variable model was also identiﬁed where
“cumulative dose” was nested within “daily dose”. Whilst the majority
of papers showed an increased risk of fracture, regardless of themethod
deﬁning risk attribution, the magnitude of this risk varied greatly. For
example, estimates of increased risk ranged from1.03per gram increase
in cumulative dose [43] to 8.16 [41] in patients ever exposed compared
to never exposed. Conversely, the lowest estimate of risk was 0.17 [24]
for patients currently using glucocorticoids compared to those not cur-
rently using glucocorticoids and suggested a protective effect. However,
this contradicted most other ﬁndings. Even within analytic models,
there was marked variation in the results.
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for drugs that are taken dynamically through time such as glucocorti-
coids (see Fig. 2).
The “current use” deﬁnition examines the association between the
fracture and whether the patient was exposed to glucocorticoids on
the day of the fracture, hence important assumptions for this model
are that any prior glucocorticoid exposure does not affect the risk of
fracture, and the dose of glucocorticoids on the day of fracture is not im-
portant. The wide range of results for “current use”, from 1.33 [13] to
4.15 [15], may reﬂect variability in patterns of prior use between stud-
ies. Indeed, the mean length of follow up ranged from 1 year to
12.6 years for papers reporting “current use”, allowing very different
prior exposure patterns. The “ever use” deﬁnition, conversely, assumes
that all historical therapy affects the risk of fracture, but this is regard-
less of how recently the therapy was taken. The range of results was
harder to compare for this model since only P-values were reported in
most cases.
The “daily dose” deﬁnition assumes that the strength of the dose on
the day of fracture has the largest effect on fracture risk however it typ-
ically does not consider historical doses. This method has an advantage
in that it provides clinicians and patientswith information about the ex-
tent to which increasing dose is likely to affect the risk of fracture. For
example, de Nijs et al. [25] showed that there was an increased fracture
risk of about 16% per mg per day. Furthermore, this deﬁnition of gluco-
corticoid exposure assumes that the risk of fracture increases linearly
with the increase of dose. This means that it is impossible to examine
whether the change to the risk of fracture tapers at some value of
daily dose.
The “cumulative dose” method assumes that all current and prior
glucocorticoids have equal impact on fracture risk regardless of how re-
cently they were taken. However, calculating cumulative dose can be
difﬁcult which may lead to misclassiﬁcation and imprecision of esti-
mates. The dynamic regeneration and repair of bone suggests cessation
of glucocorticoids might be followed recovery in bone health as shown
by Van Staa et al. [10]. The effect of historic doses probably, therefore,
has less of an impact on fracture risk compared to more recent doses.
Furthermore, the “cumulative dose”method is unable to distinguish be-
tween long term, low dose treatments and short-term, high dose treat-
ments. This disadvantage can be overcome by using a multi-variable
model and nesting cumulative dose within daily dose such as the
models used by Van Staa et al. [46] and De Vries et al. [26]. For example,
this allowed for differentiation between patients who had taken be-
tween 2.5 and 4.9 mg/day with a total cumulative dose of N1 g and
15–29.9 mg/daywith a cumulative dose of N1 g. In this case the relative
risk (95% CI) were 1.41 (1.23, 1.62) and 2.84 (2.45, 3.30) suggesting the
higher dose for short periods of time has a greater impact on fracture
risk.
The “time variant” method assumes that the duration spent on glu-
cocorticoids affects fracture risk. Within this model, the majority of re-
sults found an increased fracture risk with increasing duration of use.
However, the results are difﬁcult to compare as they consider the unit
of time as years [20,21,27,29,47], months [40,44] and days [45].
Beyond the ﬁvemodels described above, and illustrated in Fig. 1, Su-
giyama [41,42] also included the effect of pulse therapy, initial daily
dose and “number of glucocorticoid dose increases” as methods for de-
ﬁning glucocorticoid exposure. Van Staa et al. [9] considered the num-
ber of prescriptions received in the past 6 months as a measure of
glucocorticoid dose with the participants split into 3 categories (0, 1–
2, N2 prescriptions). They found that patients with 2 or more prescrip-
tions increased their risk by 160% whereas patients with no prescrip-
tions increased their risk by only 30% compared to patients without RA.
None of the models described above considered dose, duration and
timing simultaneously, despite it being probable that all are important.
Furthermore, no study made a comparison of how recency of glucocor-
ticoid exposure affects the risk of fractures. One novel method that does
consider dose, duration, and timing is the weighted cumulative dosemodel [48]. This method has previously been used to investigate the
risk of infection with glucocorticoid therapy [49]. This method weights
the dose by how recent it is to the occurrence of the adverse event of in-
terest. A cubic spline curve is ﬁtted allowing the data to deﬁne the shape
of the weighting curve and hence determinewhich time points provide
the largest effect of the glucocorticoids, in combinationwith the dosage.
Whilst many studies consider the dose-dependent risk irrespective of
treatment duration, thismethod allows risk estimates for any given pat-
tern of glucocorticoid use and can thus allow the comparison of the
same dose but taken for different durations. For example, Dixon et al.
[49] found that 5 mg prednisolone equivalent taken for 3, 6, 12 months
or three years conferred an increased risk of serious infection of 11%,
30%, 55 and 100%, respectively, compared to non-use. This shows that
historical doses, and the duration of such use, are important. It also al-
lows consideration of the same dose and duration pattern, but taken
at different times with respect to the event of interest, thereby allowing
the exploration of recovery from risk (for example, six months at 5 mg/
day for the last sixmonths, versus sixmonths at 5mg/day started a year
ago and discontinued six months ago).
Considering the limitations of this review, abstracts were screened
and data extracted by a single reviewer. Only the two leading databases
were included in the search for publications and papers not written in
the English language were also excluded from the review. As the key
focus of the publication was to identify the differences in methodology,
this was felt to be reasonable. Within the publications, it was unclear
whether the glucocorticoids were prescribed for RA or another illness.
Despite a possible alternative indication within an RA population, any
observed relationship would remain valid unless the effect of glucocor-
ticoid therapy is modiﬁed signiﬁcantly by the indication. Furthermore,
this review spans the development of anti-TNF therapy for use in in-
ﬂammatory conditions. Due to the potential direct impact of biologic
therapy on fracture risk, a comparison between studies undertaken be-
fore and after 2000would be useful. However, due to the heterogeneity
of the study designs included within this review it is difﬁcult to make a
direct comparisonwithin any givenmethod between pre and post 2000
since there maybe unmeasured confounding.
5. Summary
There are ﬁve main methods by which fracture risk has been attrib-
uted to glucocorticoid exposure, none of which consider the dose, dura-
tion and timing of treatment. This means risk estimates will rarely
consider the complex individual patterns of steroid treatment, and
will thus not give an accurate fracture risk assessment for an individual
patient. There are now opportunities with advanced analytical methods
to incorporate all these factors into a single model, allowing the gener-
ation of risk estimates for any given pattern of steroid exposure.
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Appendix 1: Search terms used
The explode option (exp) was used for terms of particular interest
where the papers of interest may ﬁt into multiple subcategories.
The terms categorised under glucocorticoids included:
• Triamcinolone
• Dexamethasone
• Prednisone
• Prednisolone
• Methylprednisolone
• Budesonide
• Bethamethasone
• Cortisone
• Glucocorticoids
• exp Corticosteroids
• Terms for the drug adjacent within 2 words (adj2) to methods of tak-
ing the drug, where terms for the drug included glucocorticoid*,
Glucocorticosteroid*, Corticosteroid* and steroid* andmethods of tak-
ing the drug included therap*, prescript*, use*, treat*, oral, and tablet.
• The terms categorised under fracture included:
• Fracture*
• Terms categorised under rheumatoid arthritis included:
• Rheumatoid arthritis
• exp. Arthritis, Rheumatoid
• Inﬂammatory polyarthritis
• Inﬂammatory arthritis
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